

17 June 2024

ASX Announcement

Nasodine Phase 1 Paper Published

- **Nasodine Phase 1 trial published in prestigious peer-reviewed journal**
- **First comprehensive safety trial of any povidone-iodine nasal spray**
- **Publication will support Nasodine in international markets**

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that its Phase 1 trial of Nasodine® Nasal Spray (“Nasodine”) has now been published in the *International Forum of Allergy and Rhinology* (IFAR), a high impact and highly ranked journal. The paper is titled “Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone-iodine nasal spray (Nasodine)”. The full paper is available online at: <https://doi.org/002/alr.23389>

The conclusion of the paper reads: “The 0.5% PVP-I nasal spray (Nasodine) was safe and well tolerated and did not cause clinically significant elevation of serum iodine in euthyroid adults, when applied four times daily for 5 days, at a dose of 1.12 mL (four sprays per nostril).”

“This published paper is the first clinical safety assessment of a PVP-I nasal spray that addresses systemic iodine absorption by the nasal route. Its publication in IFAR is an important endorsement of the importance of this data,” said Executive Chairman, Dr Peter Molloy.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine. The Company has successfully developed a povidone-iodine nasal spray (Nasodine® Nasal Spray) and filed international trademarks and multiple patents on the product. The Company has also completed six clinical trials for the nasal spray, which have affirmed the product’s safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Firebrick is now commercialising Nasodine in international markets.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com